Collagen Corp. and ABC's 20/20
This article was originally published in The Gray Sheet
Executive SummaryAt a March 30 session of the HIMA annual meeting, John Stossel, reporter for the ABC television program 20/20, said he will consider doing a story that provides data from studies indicating that use of Collagen's Zyderm/Zyplast injectable collagen products is not associated with autoimmune disease. A Stossel report on the Feb. 22, 1991 broadcast of 20/20 highlighted claims from individuals who believe that Collagen's products have caused autoimmune disorders ("The Gray Sheet" March 4, 1991, p. 6). Noting that plaintiffs attorneys told him that use of Collagen's products "would lead to all kinds of autoimmune disease," Stossel told the HIMA gathering that "given that the product is in a lot of places, you would think [autoimmune disease] would start showing up all over, and so far it hasn't. And if that continues down the road, and collagen is widely accepted, then I think...I should do a followup story" on how "the emphasis of our story was wrong".
You may also be interested in...
With positive data from two Phase III trials, Incyte hopes to file an NDA this year for topical Jakafi in mild-to-moderate AD.
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.